Restasis Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Phosphatidylserine accelerates wound healing and reduces necrosis in the rats: Growth factor activation
In conclusion, these findings suggest the potential of PS application in the healing of wounds and control of necrosis development after surgery or skin injuries.PMID:38408759 | DOI:10.1111/1440-1681.13849 (Source: Clinical and Experimental Pharmacology and Physiology)
Source: Clinical and Experimental Pharmacology and Physiology - February 26, 2024 Category: Drugs & Pharmacology Authors: Partow Mirzaee Saffari Pooria Asili Sadaf Eshraghi Ahad Muhammadnejad Ahmad Reza Dehpour Ramin Goudarzi Alireza Partoazar Source Type: research

Tacrolimus-induced cholestatic hepatotoxicity after renal transplantation: a case report
ConclusionIt seems that the patient ’s hyperbilirubinemia was due to tacrolimus, and the patient’s bilirubin decreased after stopping tacrolimus. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - February 26, 2024 Category: General Medicine Source Type: research

Modern practical management of acute severe colitis
AbstractAcute severe ulcerative colitis (ASUC) is one of life-threatening complications that occur in one-fifth of ulcerative colitis (UC) patients with significant morbidity and an estimated mortality rate up to 1%. There are no validated clinical scoring systems for ASUC. Intravenous corticosteroids remain the cornerstone for the management of ASUC patients However, one-third of patients are steroid refractory and require colectomy in the pre-biologic era or salvage therapy in the post-biologic era. The currently available predictors of non-response to steroids and salvages therapy are sub-optimal. Furthermore, there is ...
Source: Indian Journal of Gastroenterology - February 26, 2024 Category: Gastroenterology Source Type: research

Progress in medical therapy in aplastic anemia: why it took so long?
Int J Hematol. 2024 Feb 26. doi: 10.1007/s12185-024-03713-3. Online ahead of print.ABSTRACTThe treatment of aplastic anemia (AA) has significantly advanced in the last 50 years, evolving from a fatal condition to one where survival rates now exceed 80-85%. Hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have become the primary treatments, with the latter widely adopted due to factors like the scarcity of compatible donors, patient age, comorbidities, and limited HSCT access. A therapy breakthrough was the introduction of antithymocyte globulin (ATG), with its effectiveness further boosted...
Source: International Journal of Hematology - February 25, 2024 Category: Hematology Authors: Phillip Scheinberg Source Type: research

Anti-psoriatic characteristics of ROCEN (topical Arthrocen) in comparison with Cyclosporine A in a murine model
Topical ROCEN (Roc), liposomal arthrocen hydrogel, is a robust anti-inflammatory formulation which has been developed for skin diseases such as eczema. Therefore, we aimed to evaluate the efficacy of Roc 2% on... (Source: BMC Complementary and Alternative Medicine)
Source: BMC Complementary and Alternative Medicine - February 24, 2024 Category: Complementary Medicine Authors: Ramin Goudarzi, Min-Ho Kim and Alireza Partoazar Tags: Research Source Type: research

Successful treatment of acrodermatitis continua of Hallopeau coexisting with generalized pustular psoriasis with spesolimab: a case report
We report an Asian patient with a 16-year-history of GPP and ACH with marked pustulosis on the nail bed and onychodystrophy. He received conventional systemic regimen acitretin, cyclosporine and biologics adalimumab and secukinumab, but experienced relapse for skin lesions and refractory for nail lesions. He was then treated with a single dose of spesolimab in combination with secukinumab, which resulted in skin clearance and nearly complete resolution of nail lesions over a 32-week period. Our observation suggests that spesolimab should be considered for the treatment of ACH, especially in the patients with intractable na...
Source: Frontiers in Immunology - February 23, 2024 Category: Allergy & Immunology Source Type: research

Better Rejection-Free Survival at Three Years in Kidney Transplant Recipients With Model-Informed Precision Dosing of Mycophenolate Mofetil
Clin Pharmacol Ther. 2024 Feb 19. doi: 10.1002/cpt.3206. Online ahead of print.ABSTRACTThe clinical impact of individual dose adjustment of mycophenolate mofetil is still debated, due to conflicting results from randomized clinical trials. This retrospective study aimed to compare 3-year rejection-free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without mycophenolate mofetil model-informed precision dosing (MIPD). MIPD is defined here as mycophenolic acid area under the curve (AUC0-12h ) estimation using a limited sampling strategy, pharmacokinetic models and Bayesian estimators; ...
Source: Clinical Pharmacology and Therapeutics - February 19, 2024 Category: Drugs & Pharmacology Authors: Claire Villeneuve Antoine Humeau Caroline Monchaud Marc Labriffe Jean-Phillipe Rerolle Lionel Couzi Pierre-Fran çois Westeel Isabelle Etienne Nassim Kamar Mathias B üchler Antoine Thierry Pierre Marquet Source Type: research

Clinical outcomes, survival, and predictors in lower-risk myelodysplastic syndrome patients treated with cyclosporine A
CONCLUSION: CSA is a safe treatment and can significantly improve cytopenias in a substantial proportion of patients with MDS, especially in individuals with hypocellular bone marrow. However, CSA is not associated with PFS or OS.PMID:38368853 | DOI:10.1159/000537773 (Source: Acta Haematologica)
Source: Acta Haematologica - February 18, 2024 Category: Hematology Authors: Yingjia Lu Lina Zhang Weiying Qu Zhou Feng Yuan Deng Lin Zhao Source Type: research

A case of Stevens-Johnson syndrome treated with oral cyclosporine
J Family Med Prim Care. 2023 Dec;12(12):3425-3428. doi: 10.4103/jfmpc.jfmpc_1162_23. Epub 2023 Dec 21.ABSTRACTStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can occur at any age and are commonly caused by adverse drug events. Rapid diagnosis of SJS/TEN is imperative, followed by immediate cessation of offending agent and induction of appropriate treatment. Cyclosporine, a calcineurin inhibitor, has been reported to have a promising therapeutic effect in SJS/TEN patients with few side effects. Diagnosis of SJS/TEN in children is especially challenging as many of the symptoms mimic that of an upper respi...
Source: Herpes - February 16, 2024 Category: Infectious Diseases Authors: Victoria Griffith Amanda Ramnot Sydney R Resnik Barry I Resnik Source Type: research

A case of Stevens-Johnson syndrome treated with oral cyclosporine
J Family Med Prim Care. 2023 Dec;12(12):3425-3428. doi: 10.4103/jfmpc.jfmpc_1162_23. Epub 2023 Dec 21.ABSTRACTStevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) can occur at any age and are commonly caused by adverse drug events. Rapid diagnosis of SJS/TEN is imperative, followed by immediate cessation of offending agent and induction of appropriate treatment. Cyclosporine, a calcineurin inhibitor, has been reported to have a promising therapeutic effect in SJS/TEN patients with few side effects. Diagnosis of SJS/TEN in children is especially challenging as many of the symptoms mimic that of an upper respi...
Source: Primary Care - February 16, 2024 Category: Primary Care Authors: Victoria Griffith Amanda Ramnot Sydney R Resnik Barry I Resnik Source Type: research